William N. Hait , Eric Rubin , Elizabeth Alli , Susan Goodin
{"title":"Tubulin Targeting Agents","authors":"William N. Hait , Eric Rubin , Elizabeth Alli , Susan Goodin","doi":"10.1016/j.uct.2006.10.001","DOIUrl":null,"url":null,"abstract":"<div><p>Drugs<span><span> that target tubulin, including the vinca alkaloids and </span>taxanes<span><span>, represent some of the most effective anticancer medications. Both natural-product and semisynthetic compounds show a remarkable spectrum of </span>anticancer activity<span><span>. In this chapter, we review new developments in cancer biology and pharmacology that shed light on the effectiveness of tubulin binding agents. In addition, we highlight newer agents and several drugs in </span>preclinical development that hold considerable promise for the future. Finally, we comment on the rational selection of patients for chemotherapy and a more mechanistic approach to using these drugs in combinations.</span></span></span></p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.10.001","citationCount":"52","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Update on cancer therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1872115X06000703","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 52
Abstract
Drugs that target tubulin, including the vinca alkaloids and taxanes, represent some of the most effective anticancer medications. Both natural-product and semisynthetic compounds show a remarkable spectrum of anticancer activity. In this chapter, we review new developments in cancer biology and pharmacology that shed light on the effectiveness of tubulin binding agents. In addition, we highlight newer agents and several drugs in preclinical development that hold considerable promise for the future. Finally, we comment on the rational selection of patients for chemotherapy and a more mechanistic approach to using these drugs in combinations.